Trial Profile
A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Regorafenib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PRODIGE 58; REGIRI
- 24 Oct 2023 Preliminary Results (n=34) assessing Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma presented at the 48th European Society for Medical Oncology Congress
- 21 Jan 2023 Primary endpoint To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of overall survival (OS)) has not been met according to results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium